Press Release: Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration

Press Release: Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
CANNANNEW REPORT

March 08, 2022  Source: Clearmind Medicine Inc.   The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced a Collaboration agreement (the “Collaboration”) with SciSparc Ltd. (NASDAQ: SPRC). The two companies will explore the potential for the creation of innovative compounds in the psychedelic area. The Collaboration will address, inter alia, examining the benefit of integrating the core technologies of each company by combining molecules from their respective development pipelines. The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. “Our aim is to develop innovative, effective and safe psychedelic-derived therapeutics that could transform the mental health pharmaceutical market,” said Clearmind CEO Adi Zuloff-Shani. “Clearmind has established a number of R&D partnerships, in order to continue strengthening its IP portfolio, including with leading academic, research and medical institutions. We’re excited about the Collaboration with SciSparc, which we consider symbiotic, and expecting to reveal more details about the science behind the Collaboration soon.” The Collaboration is a “Related Party Transaction” (as such term is defined in “Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions” (the “Instrument”)) as certain directors and officers of the Company are also or have been directors and officers of SciSparc Ltd. The Company will comply with the Instrument but expects to rely on the exemptions available in Sections 5.5 (a) and 5.7 (a) of the Instrument as they relate to the Collaboration. About Clearmind Medicine Inc. Clearmind is…

Excerpt only …
READ MORE BELOW
Source : Press Release: Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.